血清血管内皮生长因子在结直肠癌诊治中的研究进展

doi:10.20047/j.issn1673-7210.2023.12.07

Abstract
Figure/Table
References (45)
Related Citation (15)

Download: PDF (517 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract As the third largest cancer in the world, colorectal cancer has seriously threatened the life and health of Chinese residents. The vascular endothelial growth factor (VEGF) family plays an important role in the progression of colorectal cancer. In the special hypoxic microenvironment of tumors, multiple subtypes of VEGF bind to receptors respectively to affect the generation of tumor blood vessels and lymphatic vessels, thus regulating tumor proliferation and metastasis. Compared with VEGF in tissues, serum VEGF is easier to monitor and also plays a role in the diagnosis and treatment of colorectal cancer. It is not only related to precancerous lesions, diagnosis and stage of colorectal cancer, but also related to patients’ recurrence, survival time, treatment effect and other prognostic conditions, which is expected to become a new important indicator in the diagnosis and treatment of colorectal cancer. This article discusses the research progress of serum VEGF in the diagnosis and treatment of colorectal cancer, and specifically lists its role in the diagnosis and prognosis of colorectal cancer, so as to analyze its further clinical application.

Key words： Colorectal cancer Vascular endothelial growth factor Angiogenesis Tumor progression Tumor recurrence

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Cheng MIN Jie SU Haichuan

Cite this article:

YANG Cheng MIN Jie SU Haichuan. Research progress of serum vascular endothelial growth factor in the diagnosis and treatment of colorectal cancer[J]. 中国医药导报, 2023, 20(12): 35-39.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.12.07 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I12/35

[1] Siegel RL，Miller KD，Fuchs HE，et al. Cancer statistics，2022 [J]. CA Cancer J Clin，2022，72（1）：7-33.
[2] Mody K，Baldeo C，Bekaii-Saab T. Antiangiogenic Therapy in Colorectal Cancer [J]. Cancer J，2018，24（4）：165-170.
[3] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[4] Dekker E，Tanis PJ，Vleugels JLA，et al. Colorectal cancer [J]. Lancet，2019，394（10207）：1467-1480.
[5] Goel HL，Mercurio AM. VEGF targets the tumour cell [J]. Nat Rev Cancer，2013，13（12）：871-882.
[6] Karayiannakis AJ，Syrigos KN，Zbar A，et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery [J]. Surgery，2002，131（5）：548-555.
[7] Kwon KA，Kim SH，Oh SY，et al. Clinical significance of preoperative serum vascular endothelial growth factor，interleukin-6，and C-reactive protein level in colorectal cancer [J]. BMC Cancer，2010，10：203.
[8] Shibuya M. Vascular Endothelial Growth Factor （VEGF） and Its Receptor （VEGFR） Signaling in Angiogenesis：A Crucial Target for Anti-and Pro-Angiogenic Therapies [J]. Genes Cancer，2011，2（12）：1097-1105.
[9] Maniscalco WM，Angio CTD. Vascular endothelial growth factor [M]. 2006：413-418.
[10] Lohela M，Bry M，Tammela T，et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis [J]. Curr Opin Cell Biol，2009，21（2）：154-165.
[11] Dakowicz D，Zajkowska M，Mroczko B. Relationship between VEGF Family Members，Their Receptors and Cell Death in the Neoplastic Transformation of Colorectal Cancer [J]. Int J Mol Sci，2022，23（6）：3375.
[12] Melincovici CS，Bo■ca AB，u■man S，et al. Vascular endothelial growth factor （VEGF）-key factor in normal and pathological angiogenesis [J]. Rom J Morphol Embryol，2018，59（2）：455-467.
[13] Ferrara N，Gerber H，Lecouter J. The biology of VEGF and its receptors [J]. Nat Med，2003，9（6）：669-676.
[14] Sidorkiewicz I，Zbucka-Kr?誰towska M，Zar?誰ba K，et al. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers [J]. BMC Cancer，2019，19：398.
[15] Yeh C，Shih L，Chang J，et al. Synchronous vascular endothelial growth factor protein profiles in both tissue and serum identify metastasis and poor survival in colorectal cancer [Z]. Sci Rep，2019：9，4228.
[16] Jubb AM，Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer [J]. Lancet Oncol，2010，11（12）：1172-1183.
[17] Mohamed SY，Mohammed HL，Ibrahim HM，et al. Role of VEGF，CD105，and CD31 in the Prognosis of Colorectal Cancer Cases [J]. J Gastrointest Cancer，2019，50（1）：23- 34.
[18] Abid M，Qadir F，Salihi A. Association between the serum concentrations and mutational status of IL-8，IL-27 and VEGF and the expression levels of the hERG potassium channel gene in patients with colorectal cancer [J]. Oncol Lett，2021，22（3）：665.
[19] Co■kun ?魻，?魻 Ztopuz ?魻，?魻 Zkan ?魻F. Determination of IL-6，TNF-?魱± and VEGF levels in the serums of patients with colorectal cancer [J]. Cell Mol Biol，2017，63（5）：97-101.
[20] Xu YJ，Chen WK，Zhu Y，et al. Effect of thoracic epidural anaesthesia on serum vascular endothelial growth factor C and cytokines in patients undergoing anaesthesia and surgery for colon cancer [J]. Brit J Anaesth，2014，113：i49-i55.
[21] Celen O，Kahraman I，Yildirim E，et al. Correlation of vascular endothelial growth factor （VEGF） and CEA with clinicopathological variables in colorectal cancer patients [J]. Neoplasma，2004，51（4）：293-299.
[22] Chater C，Bauters A，Beugnet C，et al. Intraplatelet Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor：New Biomarkers in Carcinoembryonic Antigen- Negative Colorectal Cancer? [J]. Gastrointest Tumors，2018，5（1/2）：32-37.
[23] Wang G，Wang Y，Yang X，et al. The expression and diagnostic value of serum levels of EphA2 and VEGF-A in patients with colorectal cancer [J]. Cancer Biomark，2021，31（4）：399-408.
[24] Comstock SS，Xu D，Hortos K，et al. Association of insulin-related serum factors with colorectal polyp number and type in adult males [J]. Cancer Epidemiol Biomarkers Prev，2014，23（9）：1843-1851.
[25] Be■ta■ R，Kaplan MA，I■ikdo■an A. The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma [J]. Hepatogastroenterology，2014， 61（130）：267-271.
[26] Miyazaki T，Okada N，Ishibashi K，et al. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer [J]. Jpn J Clin Oncol，2008，38（12）：839-843.
[27] Divella R，Daniele A，DE Luca R，et al. Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer [J]. Anticancer Res，2017，37（9）：4867-4871.
[28] Altomare DF，Rotelli MT，Pentimone A，et al. Tissue factor and vascular endothelial growth factor expression in colorectal cancer：relation with cancer recurrence [J]. Colorectal Dis，2007，9（2）：133-138.
[29] Chin KF，Greenman J，Reusch P，et al. Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer：associations with disease recurrence [J]. Eur J Surg Oncol，2003，29（6）：497-505.
[30] Mitsis M，Koliou P，Bali C，et al. In Surgical Colon Cancer Patients Extended-Duration Thromboprophylaxis （30 days） with the Highest Dose of Tinzaparin （4，500 IU s.c./q.d.） Normalizes the Postoperative VEGF Levels [J]. J Cancer，2017，8（15）：2899-2906.
[31] Alonso S，Pascual M，Salvans S，et al. Postoperative intra- abdominal infection and colorectal cancer recurrence：A prospective matched cohort study of inflammatory and angiogenic responses as mechanisms involved in this association [J]. Eur J Surg Oncol，2015，41（2）：208-214.
[32] Min BS，Kim NK，Jeong HC，et al. High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection [J]. Oncol Lett ，2012，4（1）：123-130.
[33] Lurje G，Zhang W，Schultheis AM，et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage Ⅲ colon cancer [J]. Ann Oncol，2008，19（10）：1734-1741.
[34] Pascual M，Alonso S，Salvans S，et al. Postoperative serum Vascular Endothelial Growth Factor is an independent prognostic factor of disease free survival and overall survival in patients with non metastatic colon cancer [J]. Am J Surg，2018，216（2）：255-259.
[35] Sun C，Bai Y，Jiang J，et al. Effects of laparoscopic radical surgery in the treatment of colorectal cancer and correlations of VEGF and TGF-β1 with prognosis [J]. Am J Transl Res，2021，13（11）：12887-12896.
[36] Xu H，Ren YJ，Liu K，et al. Correlations of serum VEGF and MMP-2 levels with CLM in CRC patients and effects of TACE on their expressions [J]. Eur Rev Med Pharmacol Sci，2018，22（11）：3394-3401.
[37] Bisgin A，Kargi A，Yalcin AD，et al. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer [J]. BMC Cancer，2012，12（1）：58.
[38] Beatty GL，Giantonio BJ. Bevacizumab and oxaliplatin- based chemotherapy in metastatic colorectal cancer [J]. Expert Rev Anticanc，2008，8（5）：683-688.
[39] Sümbül AT，Di■el U，Sezgin N，et al. Can serial monitoring of serum Vascular Endothelial Growth Factor （VEGF），Nitric Oxide （NO），and Angiotensin Ⅱ （ANGⅡ） levels have predictive role during Bevacizumab treatment? [J]. Med Sci Monit，2014，20：428-433.
[40] Suenaga M，Cao S，Zhang W，et al. Genetic variants in CCL5 andCCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients [J]. Int J Cancer，2019，144（10）：2567-2577.
[41] Azzariti A，Porcelli L，Brunetti O，et al. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer [J]. World J Gastroenterol，2016，22（27）：6287-6295.
[42] Chen S，Zhang Y，Zhang Y，et al. Potentiation of treatment efficacy against colon cancer of dopamine via elevating KLF2 expression in tumor vascular endothelial cells [J]. Eur Rev Med Pharmacol Sci，2017，21（21）：4860-4866.
[43] Suenaga M，Mashima T，Kawata N，et al. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer [J]. Oncotarget，2016，7（23）：34811-34823.
[44] Ying K，Chong Y，Wei W，et al. Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients [J]. Rev Assoc Med Bras（1992），2019，65（2）：177-182.
[45] Nakamura I，Shibata M，Gonda K，et al. Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition，immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system [J]. Oncol Lett，2013，5（5）：1682-1686.